HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human
| ¥4500 | |
| Z06463-100 | |
|  | |
|  | |
|  | |
| ¥4500 | |
| Z06463-100 | |
|  | |
|  | |
|  | |
| Species | Human | ||||||
| Protein Construction | 
 | ||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 50.4 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. | 


![HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06463 ELISA.jpg&file=scm_files/productFile_notes/2025/04/25/Z06463 ELISA.jpg) 
                                                    Immobilized HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-HLA-A*02:01&B2M&GP100 Antibody, hFc Tag with the EC50 of 5.6 ng/ml determined by ELISA. »
![HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06463 HPLC.png&file=scm_files/productFile_notes/2025/04/25/Z06463 HPLC.png) 
                                                    The purity of HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Humanr was greater than 95% as determined by SEC-HPLC. »
![HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06463 PAGE.png&file=scm_files/productFile_notes/2025/04/25/Z06463 PAGE.png) 
                                                    HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
![HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06463 ELISA-2.jpg&file=scm_files/productFile_notes/2025/06/05/Z06463 ELISA-2.jpg) 
                                                    Immobilized Tebentafusp, No Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer[Biotin], His & Avi, Human, His Tag with the EC50 of 21.7 ng/ml determined by ELISA. »
| Target Background | Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I and YLEPGPVTA peptide of the gp100. | 
| Synonyms | HLA0201; MHC I; gp100; Glycoprotein 100; ME20-M; P100 | 


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


